These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 30982199)
1. Clinical observation of lymphopenia in patients with newly diagnosed glioblastoma. Kim WJ; Dho YS; Ock CY; Kim JW; Choi SH; Lee ST; Kim IH; Kim TM; Park CK J Neurooncol; 2019 Jun; 143(2):321-328. PubMed ID: 30982199 [TBL] [Abstract][Full Text] [Related]
2. Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma. Mendez JS; Govindan A; Leong J; Gao F; Huang J; Campian JL J Neurooncol; 2016 Apr; 127(2):329-35. PubMed ID: 26725885 [TBL] [Abstract][Full Text] [Related]
3. Craniospinal irradiation with concomitant and adjuvant temozolomide--a feasibility assessment of toxicity in patients with glioblastoma with a PNET component. O'Leary B; Mandeville HC; Fersht N; Solda F; Mycroft J; Zacharoulis S; Vaidya S; Saran F J Neurooncol; 2016 Apr; 127(2):295-302. PubMed ID: 26842817 [TBL] [Abstract][Full Text] [Related]
4. Clinical predictors of radiation-induced lymphopenia in patients receiving chemoradiation for glioblastoma: clinical usefulness of intensity-modulated radiotherapy in the immuno-oncology era. Byun HK; Kim N; Yoon HI; Kang SG; Kim SH; Cho J; Baek JG; Chang JH; Suh CO Radiat Oncol; 2019 Mar; 14(1):51. PubMed ID: 30917849 [TBL] [Abstract][Full Text] [Related]
5. JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma. Wakabayashi T; Natsume A; Mizusawa J; Katayama H; Fukuda H; Sumi M; Nishikawa R; Narita Y; Muragaki Y; Maruyama T; Ito T; Beppu T; Nakamura H; Kayama T; Sato S; Nagane M; Mishima K; Nakasu Y; Kurisu K; Yamasaki F; Sugiyama K; Onishi T; Iwadate Y; Terasaki M; Kobayashi H; Matsumura A; Ishikawa E; Sasaki H; Mukasa A; Matsuo T; Hirano H; Kumabe T; Shinoura N; Hashimoto N; Aoki T; Asai A; Abe T; Yoshino A; Arakawa Y; Asano K; Yoshimoto K; Shibui S; J Neurooncol; 2018 Jul; 138(3):627-636. PubMed ID: 29557060 [TBL] [Abstract][Full Text] [Related]
6. Retrospective comparison of standard and escalated doses of radiotherapy in newly diagnosed glioblastoma patients treated with concurrent and adjuvant temozolomide. Guler OC; Yıldırım BA; Önal C; Topkan E Indian J Cancer; 2019; 56(1):59-64. PubMed ID: 30950447 [TBL] [Abstract][Full Text] [Related]
7. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme. Reddy K; Damek D; Gaspar LE; Ney D; Waziri A; Lillehei K; Stuhr K; Kavanagh BD; Chen C Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):655-60. PubMed ID: 22483738 [TBL] [Abstract][Full Text] [Related]
8. Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. Schiff D; Desjardins A; Cloughesy T; Mikkelsen T; Glantz M; Chamberlain MC; Reardon DA; Wen PY Cancer; 2016 Feb; 122(4):582-7. PubMed ID: 26588662 [TBL] [Abstract][Full Text] [Related]
9. Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis. Gutenberg A; Bock HC; Reifenberger G; Brück W; Giese A Acta Neurochir (Wien); 2013 Mar; 155(3):429-35. PubMed ID: 23254891 [TBL] [Abstract][Full Text] [Related]
10. Whole brain radiotherapy with concurrent temozolomide in multifocal and/or multicentric newly diagnosed glioblastoma. Lahmi L; Idbaih A; Rivin Del Campo E; Hoang-Xuan K; Mokhtari K; Sanson M; Canova CH; Carpentier A; Jacob J; Maingon P; Feuvret L J Clin Neurosci; 2019 Oct; 68():39-44. PubMed ID: 31399318 [TBL] [Abstract][Full Text] [Related]
11. Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea. Kim BS; Seol HJ; Nam DH; Park CK; Kim IH; Kim TM; Kim JH; Cho YH; Yoon SM; Chang JH; Kang SG; Kim EH; Suh CO; Jung TY; Lee KH; Kim CY; Kim IA; Hong CK; Yoo H; Kim JH; Kang SH; Kang MK; Kim EY; Kim SH; Chung DS; Hwang SC; Song JH; Cho SJ; Lee SI; Lee YS; Ahn KJ; Kim SH; Lim DH; Gwak HS; Lee SH; Hong YK Cancer Res Treat; 2017 Jan; 49(1):193-203. PubMed ID: 27384161 [TBL] [Abstract][Full Text] [Related]
12. Prognostic factors in glioblastoma patients managed with radiotherapy combined with temozolomide. Peponi E; Tourkantonis I; Tasiou I; Pavlidis N; Pentheroudakis G; Tsekeris P J BUON; 2014; 19(3):718-23. PubMed ID: 25261658 [TBL] [Abstract][Full Text] [Related]
13. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme. Chen C; Damek D; Gaspar LE; Waziri A; Lillehei K; Kleinschmidt-DeMasters BK; Robischon M; Stuhr K; Rusthoven KE; Kavanagh BD Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1066-74. PubMed ID: 20932651 [TBL] [Abstract][Full Text] [Related]
15. Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial. Malmström A; Poulsen HS; Grønberg BH; Stragliotto G; Hansen S; Asklund T; Holmlund B; Łysiak M; Dowsett J; Kristensen BW; Söderkvist P; Rosell J; Henriksson R; Acta Oncol; 2017 Dec; 56(12):1776-1785. PubMed ID: 28675067 [TBL] [Abstract][Full Text] [Related]
16. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials. Carlson JA; Reddy K; Gaspar LE; Ney D; Kavanagh BD; Damek D; Lillehei K; Chen C J Neurooncol; 2015 Jun; 123(2):251-7. PubMed ID: 25920710 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience. Zhong L; Chen L; Lv S; Li Q; Chen G; Luo W; Zhou P; Li G Radiat Oncol; 2019 Jun; 14(1):104. PubMed ID: 31196126 [TBL] [Abstract][Full Text] [Related]
18. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Sampson JH; Aldape KD; Archer GE; Coan A; Desjardins A; Friedman AH; Friedman HS; Gilbert MR; Herndon JE; McLendon RE; Mitchell DA; Reardon DA; Sawaya R; Schmittling R; Shi W; Vredenburgh JJ; Bigner DD; Heimberger AB Neuro Oncol; 2011 Mar; 13(3):324-33. PubMed ID: 21149254 [TBL] [Abstract][Full Text] [Related]
19. Neutrophil-lymphocyte ratio dynamics during concurrent chemo-radiotherapy for glioblastoma is an independent predictor for overall survival. Mason M; Maurice C; McNamara MG; Tieu MT; Lwin Z; Millar BA; Menard C; Laperriere N; Milosevic M; Atenafu EG; Mason W; Chung C J Neurooncol; 2017 May; 132(3):463-471. PubMed ID: 28332000 [TBL] [Abstract][Full Text] [Related]
20. Serial changes in lymphocyte subsets in patients with newly diagnosed high grade astrocytomas treated with standard radiation and temozolomide. Campian JL; Piotrowski AF; Ye X; Hakim FT; Rose J; Yan XY; Lu Y; Gress R; Grossman SA J Neurooncol; 2017 Nov; 135(2):343-351. PubMed ID: 28756593 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]